Cargando…

Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not

Cardiac amyloidosis (CA), caused by the deposition of insoluble amyloid fibrils, impairs different cardiac structures, altering not only left ventricle (LV) systo-diastolic function but also atrial function and the conduction system. The consequences of the involvement of the cardiac electrical syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Argirò, Alessia, Del Franco, Annamaria, Mazzoni, Carlotta, Allinovi, Marco, Tomberli, Alessia, Tarquini, Roberto, Di Mario, Carlo, Perfetto, Federico, Cappelli, Francesco, Zampieri, Mattia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687719/
https://www.ncbi.nlm.nih.gov/pubmed/36359408
http://dx.doi.org/10.3390/biomedicines10112888
Descripción
Sumario:Cardiac amyloidosis (CA), caused by the deposition of insoluble amyloid fibrils, impairs different cardiac structures, altering not only left ventricle (LV) systo-diastolic function but also atrial function and the conduction system. The consequences of the involvement of the cardiac electrical system deserve more attention, as well as the study of the underlying molecular mechanisms. This is an issue of considerable interest, given the conflicting data on the effectiveness of conventional antiarrhythmic strategies. Therefore, this review aims at summarizing the arrhythmic burden related to CA and the available evidence on antiarrhythmic treatment in this population.